Generic cell dysfunction in neurodegenerative disorders: Role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity

Neuroscientist

Volumn 13, Issue 5, 2007, Pages 519-531

  Stefani, Massimo ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Department of Biochemical Sciences ^*  (Italy)

Author keywords

Amyloid; Amyloidoses; Neurodegenerative diseases; Prefibrillar aggregates; Protein aggregation

Indexed keywords

ADAN PROTEIN; ALPHA SYNUCLEIN; AMYLIN; AMYLOID BETA PROTEIN; ANDROGEN RECEPTOR; APOLIPOPROTEIN A1; ATAXIN 1; ATRIAL NATRIURETIC FACTOR; ATROPHIN 1; BETA 2 MICROGLOBULIN; CALCITONIN; CYSTATIN C; FIBRINOGEN; GELSOLIN; HUNTINGTIN; IMMUNOGLOBULIN LIGHT CHAIN; INSULIN; OLIGOMER; PREALBUMIN; PRION PROTEIN; PROTEIN; SERUM AMYLOID A; SUPEROXIDE DISMUTASE; TATA BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN SPONGIOSIS; CEREBELLAR ATAXIA; CEREBROVASCULAR DISEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; DEMENTIA; DENTATORUBROPALLIDOLUYSIAN ATROPHY; FAMILIAL AMYLOID POLYNEUROPATHY; GENE MUTATION; HEART ATRIUM AMYLOIDOSIS; HEMODIALYSIS RELATED AMYLOIDOSIS; HEREDITARY CEREBRAL AMYLOID ANGIOPATHY; HEREDITARY KIDNEY AMYLOIDOSIS; HUMAN; HUNTINGTON CHOREA; INJECTION LOCALIZED AMYLOIDOSIS; ION PERMEABILITY; KENNEDY DISEASE; LIPID COMPOSITION; LIPID MEMBRANE; MEMBRANE PERMEABILITY; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PHOSPHOLIPID BILAYER; PHYSICAL CHEMISTRY; PRIMARY SYSTEMIC AMYLOIDOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN STRUCTURE; SECONDARY SYSTEMIC AMYLOIDOSIS; SENILE AMYLOIDOSIS; SPINOCEREBELLAR DEGENERATION; STRUCTURE ANALYSIS; SURFACE PROPERTY; THYROID MEDULLARY CARCINOMA;

AMYLOID; ANIMALS; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; SURFACE PROPERTIES;

EID: 34548726211     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858407303428     Document Type: Article

References (139)

1. Abad-Rodriguez J., Ledesma MD, Craessaerts K., Perga S., Medina M., Delacourte A., and others. 2005. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Sci 167: 953-60.
2. Aleardi AM, Bernard G., Augereau O., Malgat M., Talbot JC, Mazat JP, and others. 2005. Gradual alteration of mitochondrial structure and function by β-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomem 37: 207-25.
3. Arispe N., Doh M. 2002. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease Aβ (1-40) and (1-42) peptides. FASEB J 16: 1526-36.
4. Arispe N., Rojas E., Pollard HD 1993. Alzheimer's disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminium. Proc Natl Acad Sci U S A 89: 10940-4.
5. Baglioni S., Casamenti F., Bucciantini M., Luheshi LM, Taddei N., Chiti F., and others. 2006. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 263: 8160-7.
6. Benvenuti S., Saccardi R., Luciani P., Urbani S., Deledda C., Cellai I., and others. 2006. Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1. Exp Cell Res 312: 2592-604.
7. Bokvist M., Lindström F., Watts A., Gröbner G. 2004. Two types of Alzheimer's β-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol 335: 1039-49.
8. Broome BM and Hecht MH 2000. Nature disfavours sequence of alternating polar and non-polar amino acids: implications for amyloid genesis. J Mol Biol 296: 961-68.
9. Bucciantini M., Calloni G., Chiti F., Formigli L., Nosi D., Dobson CM, and others. 2004. Pre-fibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 279: 31374-82.
10. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., and others. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-11.
11. Butterfield AD, Drake J., Pocernich C., Castegna A. 2001. Evidence of oxidative damage in Alzeimer's disease brain: central role for amyloid β-peptide. Trends Mol Med 7: 548-54.
12. Bychkova VE, Pain RH, Ptitsyn OB 1988. The molten globule state is involved in the translocation of protein across membranes. FEBS Lett 238: 231-4.
13. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader JW, and others. 2005. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19: 2030-41.
14. Cecchi C., Baglioni S., Fiorillo C., Pensalfini A., Liguri G., Nosi D., and others. 2005. Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. J Cell Sci 118: 3459-70.
15. Chamberlain AK, MacPhee CE, Zurdo J., Morozova-Roche LA, Hill HA, Dobson CM, and others. 2000. Ultrastructural organization of amyloid fibrils by atomic force microscopy. Biophys J 79: 3282-93.
16. Chen Y., Dokholyan NV 2005. A single disulfide bond differentiates aggregation pathways of β2-microglobulin. J Mol Biol 354: 473-82.
17. Cherny D., Hoyer W., Subramaniam V., Jovin TM 2004. Doublestranded DNA stimulates the fibrillation of alpha-synuclein in vitro and is associated with the mature fibrils: an electron microscopy study. J Mol Biol 344: 929-38.
18. Chiti F., Bucciantini M., Capanni C., Taddei N., Dobson CM, Stefani M. 2001. Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. Protein Sci 10: 2541-7.
19. Chiti F., Stefani M., Taddei N., Ramponi G., Dobson CM 2003. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424: 805-8.
20. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., and others. 1999. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96: 3590-4.
21. Choi YG, Kim JL, Lee HP, Jin JK, Choi EK, Carp RI, and others. 2000. Induction of heme oxygenase-1 in the brain of scrapie-infected mice. Neurosci Lett 11: 173-6.
22. Chung J., Yang H., de Beus MD, Ryu CY, Cho K., Colòn W. 2003. Cu/Zn superoxide dismutase can form pore-like structures. Biochem Biophys Res Commun 312: 873-6.
23. Clarke G., Collins RA, Leavitt BR, Andrews DF, Hayden MR, Lumsden CJ, and others. 2000. A one-hit model of cell death in inherited neuronal degeneration. Nature 406: 195-9.
24. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, and others. 2005. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84.
25. DeMarco MI, Silveira J., Caughey B., Daggett V. 2006. Structural properties of prion protein protofibrils and fibrils. An experimental assessment of atomic models. Biochemistry 45: 1573-82.
26. Dessolin J., Schuler M., Quinart A., De Giorgi F., Ghosez L., Ichas F. 2002. Selective targeting of synthetic antioxidants to mitochondria: towards a mitochondrial medicine for neurodegenerative diseases ? Eur J Pharmachol 447: 155-61.
27. Diaz-Nido J., Wandosell F., Avila J. 2002. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 23: 1323-32.
28. Dickson DW 1995. Correlation of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16: 285-98.
29. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr. 2002. Annular αsynuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41: 10209-17.
30. Dobson CM 1999. Protein misfolding, evolution and disease. Trends Biochem Sci 24: 329-32.
31. Dobson CM 2001. The structural basis of protein folding and its links with human disease. Phil Trans R Soc Lond B 356: 133-45.
32. Dobson CM 2003. Protein folding and misfolding. Nature 426: 884-90.
33. Ehahalt R., Keller P., Haass C., Thiele C., Simons K. 2003. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113-23.
34. Fändrich M., Dobson CM 2002. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J 21: 5682-90.
35. Ferreiro E., Resende R., Costa R., Oliveira CR, Pereira Cmf. 2006. An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol Dis 23: 669-78.
36. Gong Y., Chang I., Viola KI, Lacor PN, Lambert MP, Finch CE, and others. 2003. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100: 10417-22.
37. Guentchev M., Voigtlander T., Haberler C., Groschup MH, Budka H. 2000. Evidence for oxidation stress in experimental prion disease. Neurobiol Dis 7: 270-3.
38. Gujiarro JI, Sunde M., Jones JA, Campbell ID, Dobson, CM 1998. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 95: 4224-8.
39. Hancock Rew, Scott MG 2000. The role of antimicrobial peptides in animal defences. Proc Natl Acad Sci USA 97: 8856-61.
40. Harper JB, Wong SS, Lieber CM, Lansbury PT 1999. Assembly of Abeta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38: 8972-80.
41. Hirakura Y., Carreras I., Sipe JD, Kagan BL 2002. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid 9: 13-23.
42. Hotze EM, Heuck AP, Czajkowsky M., Shao Z., Johnson AE, Tweten R. 2002. Monomer-monomer interactions drive the prepore to pore conversion of a β-barrel-forming cholesterol-dependent cytolysin. J Biol Chem 277: 11597-605.
43. Hoyer W., Cherny D., Subramaniam V., Jovin TM 2004. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy. J Mol Biol 340: 127-39.
44. Huff ME, Balch WE, Kelly JW 2003. Pathological and functional amyloid formation orchestrated by the secretory pathway. Curr Opin Struct Biol 13: 674-82.
45. Hyun D-H., Lee MH, Hattori N., Kubo S-I., Mizuno Y., Halliwell B., and others. 2002. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 277: 28572-7.
46. Iwata A., Christianson JC, Bucci M., Ellerby LM, Nukina N., Forno LS, and others. 2005. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci USA 102: 13135-40.
47. Jiménez JL, Nettleton EJ, Bouchard M., Robinson CV, Dobson CM, Saibil HR 2002. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci USA 99: 9196.
48. Kakio A., Nishimoto S-L., Kozutsumi Y., Matsuzaki K. 2003. Formation of membrane-active form of amyloid β-protein in raft-like model membranes. Biochim Biophys Res Commun 303: 514-8.
49. Kakio A., Nishimoto SL, Yanagisawa K., Kozutsumi Y., Matsuzaki K. 2002. Interaction of amyloid β-protein with various gangliosides in the raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41: 7385-90.
50. Kawahara M. 2004. Disruption of calcium homeostasis in the pathogenesis of Alzheimer's disease and other conformational diseases. Curr Alz Res 1: 87-95.
51. Kawahara M., Kuroda Y., Arispe N., Rojas E. 2000. Alzheimer's βamyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevation by a common mechanism in a hypopthalamic GnRH neuronal cell line. J Biol Chem 275: 14077-83.
52. Kayed R., Head E., Thompson JL, McIntire TM, Milton SC, Cotman CW, and others. 2003. Common structure of soluble amyloid oligomers implies common mechanisms of pathogenesis. Science 300: 486-9.
53. Kazlauskaite J., Senghera N., Sylvester I., Vénien-Bryan C., Pinheiro Tjt. 2003. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochemistry 42: 3295-304.
54. Keller JN, Huang FF, Markesbery WR 2002. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98: 149-56.
55. Kelly J. 1998. Alternative conformation of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8: 101-6.
56. Knight JD, Miranker AD 2004. Phospholipid catalysis of diabetic amyloid assembly. J Mol Biol 341: 1175-87.
57. Koudinov AR, Koudinova NV 2005. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J Neurol Sci 229-30: 233-40.
58. Kourie JI 1999. Synthetic C-type mammalian natriuretic peptide forms large cation selective channels. FEBS Lett 445: 57-62.
59. Kourie JI 2001. Mechanisms of amyloid β protein-induced modification in ion transport systems: implications for neurodegenerative diseases. Cell Mol Neurobiol 21: 173-213.
60. Kourie JI, Henry CL 2002. Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin Exp Pharmacol Physiol 29: 741-53.
61. Kourie JI, Shorthouse AA 2000. Properties of cytotoxic peptide-induced ion channels. Am J Physiol Cell Physiol 278: C1063-87.
62. Kranenburg O., Kroon-Batenburg Lmj, Reijerkerk A., Wu Y-P., Voest EE, Gebbink, Mfbg. 2003. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett 539: 149-55.
63. Lacor PN, Buniel MC, Chang L., Fernandez SJ, Gong Y., Viola KL, and others. 2004. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24: 10191-200.
64. Lane NJ, Balbo A., Fukuyama R., Rapoport SI, Galdzick Z. 1998. The ultrastructural effects of beta-amyloid peptide on cultured PC12 cells: changes in cytoplasmic and intramembranous features. J Neurocytol 27: 707-18.
65. Lashuel HA, Hartley D., Petre BM, Walz T., Lansbury PT 2002. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291.
66. Lashuel HA, Petre BM, Wall J., Simon M., Nowak RJ, Walz T., and others. 2002. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322: 1089-102.
67. Lee DW, Sohn HO, Lim HB, Lee YG, Kim YS, Carp RJ, and others. 1999. Alteration of free radical metabolism in the brain of mice infected with scrapie agent. Free Rad Res 30: 499-507.
68. Lee G., Pollard HB, Arispe N. 2002. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 23: 1249-63.
69. Lesné S., Koh MT, Kotlinek L., Kayed R., Glabe CG, Yang A., and others. 2006. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-7.
70. Lin MC, Mirzabekov T., Kagan BL 1997. Channel formation by a neurotoxic prion protein fragment. J Biol Chem 272: 44-7.
71. Litvinovich SV, Brew SA, Aota S., Akiyama SK, Haudenschild C., Ingham, KC 1998. Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. J Mol Biol 280: 245-58.
72. Lorenzo A., Yankner BA 1994. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91: 12243-7.
73. Lührs T., Ritter C., Adrian M., Riek-Loher D., Bohrmann B., Döbeli H., and others. 2005. 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc Natl Acad Sci USA 102: 17342-7.
74. Lührs T., Zahn R., Wüthrich K. 2006. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. J Mol Biol 357: 833-41.
75. Mason RP, Shoemaker WJ, Shajenko L., Chambers TE, Herbette LG 1992. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 13: 413-9.
76. Mattson MP 1999. Impairment of membrane transport and signal transduction systems by amyloidogenic proteins. Methods Enzymol 309: 733-68.
77. Milhavet O., Lehmann S. 2002. Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Res Rev 38: 328-39.
78. Mirzabekov TA, Lin MC, Kagan, BL 1996. Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 271: 1988-92.
79. Moreira PI, Santos MS, Moreno A., Rego AC, Oliveira C. 2002. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J Neurosci Res 15: 257-67.
80. Necula M., Chirita C., Kuret J. 2003. Rapid anionic micelle-mediated α-synuclein fibrillization in vitro. J Biol Chem 278: 46674-80.
81. Nelson R., Sawaya M., Balbirnie M., Madsen A., Riekel C., Grothe R., and others. 2005. Structure of the cross-β spine of amyloid fibrils. Nature 435: 773-8.
82. Orth M., Schapira AH 2002. Mitochondrial involvement in Parkinson's disease. Neurochem Int 40: 533-41.
83. Pappolla MA, Omar RA, Chyan YJ, Ghiso J., Hsiao K., Bozner P., and others. 2001. Induction of NADPH cytochrome P450 reductase by the Alzheimer β-protein: amyloid as a "foreign body." J Neurochem 78: 121-8.
84. Pedersen JS, Dikov D., Flink JL, Hjuler HA, Christiansen G., Otzen DE 2006. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol 355: 501-23.
85. Pepys MB 1995. Amyloid, familial Mediterranean fever, and acute phase response-amyloidosis. In: Wheaterall DJ, Ledingham JG, Warrel DA, editors. Oxford Textbook of Medicine. 3 rd ed. Oxford (UK): Oxford University Press. p 1512-24.
86. Pepys MB, Herbert J., Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, and others. 2002. Targeted pharmaceutical depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417: 254-9.
87. Perutz MF, Windle AH 2001. Cause of neuronal death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412: 143-4.
88. Petkova AT, Buntkowsky G., Dyda F., Leapman RD, Yau WM, Tycko R. 2004. Solid state NMR reveals a pH-dependent antiparallel β-sheet registry in fibrils formed by a β-amyloid peptide. J Mol Biol 335: 247-60.
89. Petkova AT, Leapman RD, Guo Z., Yau WM, Mattson MP, Tycko R. 2005. Self-propagating, molecular level polymorphism in Alzheimer's β-amyloid fibrils. Science 307: 262-5.
90. Pieri L., Bucciantini M., Nosi D., Formigli L., Savistchenko J., Melki R., and others. 2006. The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless of their aggregation state. J Biol Chem 281: 15337-44.
91. Poirier MA, Li H., Macosko J., Cail S., Amzel M., Ross CA 2002. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrillization. J Biol Chem 277: 41032-7.
92. Porat Y., Kolusheva S., Jelinek R., Gazit E. 2003. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42: 10971-7.
93. Prusiner SB, Scott MR, deArmond SJ, Cohen FE 1998. Prion Protein Biology Cell 93: 337-48.
94. Puchtler H., Sweat F. 1965. A review of early concepts of amyloid in context with contemporary chemical literature from 1839 to 1859. J Histochem Cytochem 14: 123-35.
95. Qin L., Liu Y., Cooper C., Liu B., Wilson B., Hong JS 2002. Microglia enhance β-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 83: 973-83.
96. Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., and others. 2005. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 102: 10427-32.
97. Relini A., Canale C., De Stefano S., Rolandi R., Giorgetti S., Stoppini M., and others. 2006. Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem 281: 16521-9.
98. Relini A., Torrassa S., Rolandi R., Gliozzi A., Rosano C., Canale C., and others. 2004. Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. J Mol Biol 338: 943-57.
99. Richardson JS, Richardson DC 2000. Natural b-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc Natl Acad Sci USA 99: 2754-57.
100. Ross CA 2002. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35: 819-22.
101. Rousseau S., Serrano L., Schymkowitz JW 2006. How evolutionary pressure against protein aggregation shaped chaperone specificity. J Mol Biol 355: 1037-47.
102. Sarnataro D., Campana V., Paladino S., Stornaiuolo M., Nitsch L., Zurzolo C. 2004. PrPc association with lipid rafts in the early secretory pathway stabilizes its cellular conformation. Mol Biol Cell 15: 4031-42.
103. Scwarz R., Istrail S., King J. 2001. Frequencies of amino acid strings in globular protein sequences indicate suppression of blocks of consecutive hydrophobic residues. Protein Sci 10: 1023-31.
104. Serpell LS 2000. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 1502: 16-30.
105. Sethuraman A., Belfort G. 2005. Protein structural perturbation and aggregation on homogeneous surfaces. Biophys J 88: 1322-33.
106. Sharon R., Bar-Joseph I., Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ 2003. The formation of highly soluble oligomers of αsynuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37: 583-95.
107. Sherman MY, Goldberg AL 2001. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29: 15-32.
108. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, and others. 2005. Nature 437: 257-61.
109. Sirangelo I., Malmo C., Iannuzzi C., Mezzogiorno A., Bianco MR, Papa M., and others. 2004. Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F. J Biol Chem 279: 13183-9.
110. Smith JF, Knowles Tpj, Dobson CM, MacPhee CE, Welland ME 2006. Characterization of the nanoscale properties of individual amyloid fibrils. Proc Natl Acad Sci USA 103: 15806-11.
111. Sousa MM, Cardoso I., Fernandes R., Guimaraes A., Saraiva MJ 2001. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy. Am J Pathol 159: 1993-2000.
112. Squier TC 2001. Oxidative stress and protein aggregation during biological aging. Exp Gerontol 36: 1539-50.
113. Stefani M. 2004. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739: 5-25.
114. Stefani M., Dobson CM 2003. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81: 678-99.
115. Suk JY, Zhang F., Balch WE, Linhardt RJ, Kelly JW 2006. Heparin accelerates gelsolin amyloidogenesis. Biochemistry 45: 2234-42.
116. Svanborg C., Agerstam H., Aronson A., Bjerkvig R., Duringer C., Fischer W., and others. 2003. HAMLET kills tumor cells by an apoptosislike mechanism-cellular, molecular, and therapeutic aspects. Adv Cancer Res 88: 1-29.
117. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. 1996. βamyloid-mediated vasoactivity and vascular endothelial damage. Nature 380: 168-71.
118. Townsend M., Shankar GM, Mehta T., Walsh DM, Selkoe DJ 2006. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572: 477-92.
119. Tycko R. 2004. Progress towards a molecular-level structural understanding of amyloid fibrils. Curr Opin Struct Biol 14: 96-103.
120. Uversky VN, Fink AL 2004. Conformational constraints for amyloid fibrillization: the importance of being unfolded. Biochim Biophys Acta 1698: 131-53.
121. Velez-Pardo C., Arroyave ST, Lopera F., Castano AD, Jimenez Del Rio M. 2001. Ultrastructure evidence of necrotic neural cell death in familial Alzheimer's disease brains bearing presenilin-1 E280A mutation. J Alzheimer Dis 3: 409-15.
122. Vendrely C., Valadie H., Bednarova L., Cardin L., Pasdeloup M., Cappadoro J., and others. 2005. Assembly of the full-length recombinant mouse prion protein I. Formation of soluble oligomers. Biochim Biophys Acta 1724: 355-66.
123. Volles MJ, Lansbury PT 2001. Vesicle permeabilization by protofibrillar α-synuclein: comparison of wild-type with Parkinson's disease linked mutants and insights in the mechanisms. Biochemistry 40: 7812-9.
124. Walsh DM, Klyubin I., Fadeeva JV, Cullen WK, Anwyl R., Wolfe MS, and others. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-9.
125. Wang L., Lashuel HA, Walz T., Colòn W. 2002. Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc Natl Acad Sci USA 99: 15947-52.
126. Wang SS, Good TA, Rymer DL 2005. The influence of phospholipid membranes on bovine calcitonin peptide's secondary structure and induced neurotoxic effects. Int J Biochem Cell Biol 37: 1656-69.
127. Wetzel R. 2002. Ideas of order for amyloid fibril structure. Structure 10: 1031-6.
128. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo AP, Rubinsztein DC 2002. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11: 1137-51.
129. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., and others. 2001. Polyglutamine expansions cause decreased CREmediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet 10: 1829-45.
130. Yamaguchi K., Katou H., Hishino M., Hasegawa K., Naiki H., Goto Y. 2004. Core and heterogeneity of β2-microglobulin amyloid fibrils as revealed by H/D exchange. J Mol Biol 338: 559-71.
131. Yan SD, Stern D., Kane MD, Kuo YM, Lampert HC, Roher AE 1998. RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. Resto Neurol Neurosci 12: 167-73.
132. Yang W., Dunlap JR, Andrews RB, Wetzel R. 2002. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11: 2905-17.
133. Yip CM, Elton EA, Darabie AA, Morrison MR, McLaurin J. 2001. Cholesterol, a modulator of membrane-associated Aβ-fibrillogenesis and neurotoxicity. J Mol Biol 311: 723-34.
134. Zhang L., Xing GQ, Barker JL, Chang Y., Maric D., Ma W., and others. 2001. α-Lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci Lett 312: 125-8.
135. Zhang YH, Leliveld SR, Kooistra K., Molenaar C., Rohn JL, Tanke HJ, and others. 2003. Recombinant apoptin multimers kill tumor cells but are non-toxic and epitope-shielded in a normal-cell-specific fashion. Exp Cell Res 289: 36-46.
136. Zhao H., Jutila A., Nurminen T., Wickström SA, Keski-Oja J., Kinnunen PK 2005. Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. Biochemistry 44: 2857-63.
137. Zhao H., Tuominen EK, Kinnunen PK 2004. Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43: 10302-7.
138. Zhu M., Souillac PO, Ionesco-Zanetti C., Carter SA, Fink AL 2002. Surface-catalyzed amyloid fibril formation. J Biol Chem 277: 50914-22.
139. Zhu YJ, Lin H., Lal R. 2000. Fresh and nonfibrillar amyloid β protein (1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AβP-channel-mediated cellular toxicity. FASEB J 14: 1244-54.